Zimmer Biomet (NYSE: ZBH) and Paragon 28 announced the commercial launch of its Phantom curved TTC nail system.
Zimmer made a decision to limit integration with Paragon 28, with the goal of maintaining Paragon 28’s pre-acquisition growth by committing to its established business structure, Zimmer CFO Suketu Upadhyay said at last year’s Morgan Stanley Global Healthcare Conference.
Today’s announcement reinforces Zimmer’s commitment to Paragon 28’s structure and innovative orthopedic technology.
“The Phantom curved TTC nail system represents a meaningful advance in our commitment to developing procedure-specific solutions that reflect the real anatomy surgeons navigate every day,” said Zimmer Biomet Global President, Albert DaCosta.
The implant’s curved design preserves soft tissue, increases torsional stability and allows for alignment reproducibility compared to traditional straight tibiotalocalcaneal (TTC) arthrodesis nail systems.
The Phantom curved TTC system follows the anatomic arc of the foot; extending from the posterior calcaneus through the subtalar joint, into the talus and along the tibial metaphysis to address limitations in straight TTC nails that rely on non-anatomic trajectories, the announcement described.
“By engineering a device around the natural circular arc of the hindfoot, we are helping surgeons achieve reproducible alignment, strong fixation, and thoughtful soft-tissue preservation for their most complex TTC fusion cases,” DaCosta said.
The new system is compatible with primary and revision TTC fusion procedures, including complex Charcot reconstruction, post-traumatic cases and failed straight nail fusion, the announcement said.
